CRISM National Guideline for the Clinical Management of Opioid Use Disorder

CRISM developed the first Canadian guideline for managing opioid use disorders. The guideline lays out the optimal strategies for the treatment of opioid addiction and recommends opioid agonist treatment with buprenorphine-naloxone as the preferred first-line treatment.

Recommendations at a glance

Recommendations at a Glance

Recommandations cliniques


Note that Health Canada has removed the requirement for practitioners to obtain a section 56 exemption to prescribe methadone, effective May 19, 2018. See the Section 56 Consultation page for more information.

Stay tuned for updates to the Guideline.

A synopsis of the Guideline was published in the Canadian Medical Association Journal (March 5, 2018) or download the PDF.